Impact of DNA Damage Response-Targeted Therapies on the Immune Response to Tumours

Area of Science:

• Oncology
• Immunology
• Genetics

Background:

• The DNA damage response (DDR) is crucial for maintaining genome stability against genotoxic stress.
• Aberrations in DDR pathways are a hallmark of cancer, presenting therapeutic targets.
• DDR inhibitors are increasingly used in cancer treatment, with many in clinical trials.

Purpose of the Study:

• To review the impact of DDR-targeted agents on the tumor-immune system crosstalk.
• To explore how DDR inhibitors modulate interactions between tumor cells and immune components.
• To understand the implications for developing novel cancer immunotherapies.

Main Methods:

• Literature review of recent studies on DDR-targeted agents and cancer immunology.
• Analysis of mechanisms by which DDR inhibitors affect immune cells directly.
• Examination of how DDR inhibitors alter tumor cell molecules critical for immune interactions.

Main Results:

• DDR-targeted agents can directly influence immune cell function.
• These agents modify tumor cell expression of molecules involved in immune recognition and response.
• The interplay between DDR defects, targeted therapies, and the immune system is complex and multifaceted.

Conclusions:

• Understanding DDR-targeted therapy's immunomodulatory effects is vital for cancer treatment.
• This knowledge can guide the rational design of combination therapies involving DDR inhibitors and immunomodulators.
• Further research into the DDR-immune crosstalk may unlock new avenues for cancer therapy.